 | Up a level |
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H-J, Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Burchert, A., Voskanyan, A., Rinaldetti, S., Goebeler, M., Dengler, J., Ho, A., Falge, C., Kanz, L., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Fuchs, R., Scheid, C., Haenel, M., Koehne, C-H, Bruemmendorf, H., Lindemann, H-W, Berdel, W. E., Staib, P., Balleisen, L., Brossart, P., Schenk, M., Zankovich, R., Geer, T., Hertenstein, B., Bildat, S., Hochhaus, A. and Hasford, J. (2017). ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV. Haematologica, 102. S. 151 - 153. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Stegelmann, F., Bangerter, M., Griesshammer, M., Hebart, H., Heidel, F., Hochhaus, A., Moehle, R., Reiter, A., Scheid, C., Kirschbaum, R., Reim, R., Sutter, U., Doehner, H., Schlenk, R. F. and Doehner, K. (2015). A phase-Ib/II study of ruxolitinib plus pomalidomide in Myelofibrosis: Data from the MPNSG-0212 Trial (NCT01644110). Oncol. Res. Treat., 38. S. 216 - 218. BASEL: KARGER. ISSN 2296-5262
Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von, Bubnoff N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). Pomalidomide plus ruxolitinib in myelofibrosis: Updated results from the MPNSG-0212 trial. Oncol. Res. Treat., 40. S. 149 - 150. BASEL: KARGER. ISSN 2296-5262
Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von Bubnoff, N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110). Haematologica, 102. S. 280 - 281. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stegelmann, F., Hebart, H., Bangerter, M., Wolleschak, D., Griesshammer, M., Koschmieder, S., Hochhaus, A., Heidel, F., Moehle, R., Reiter, A., Scheid, C., von Bubnoff, N., Kirschbaum, R., Reim, R., Sutter, U., Vetter, K., Doehner, H., Schlenk, R. F. and Doehner, K. (2016). Ruxolitinib/Pomalidomide combination therapy in myelofibrosis: Current data from the MPNSG-0212 trial. Oncol. Res. Treat., 39. S. 233 - 235. BASEL: KARGER. ISSN 2296-5262